Skip to content
    Northpond Ventures logo

    Northpond Ventures

    Cambridge, Massachusetts, United StatesFounded 2018
    www.npv.vcLinkedIn
    Biotech & Life SciencesHealthcareAIFood & AgricultureClimate & Energy

    Northpond Ventures is a multi-billion-dollar science-driven venture capital firm that builds and supports breakthrough science and technology driven businesses to create a marked impact on humanity. The firm is an active lead life science investor with offices in Cambridge, MA; San Francisco, CA; and Bethesda, MD.

    41% of their portfolio is in Biotech & Life Sciences. Deal activity increased 167% year-over-year (8 deals in the last 12 months). Average disclosed round size is $56.0M (across 109 rounds with reported amounts).

    Find people at Northpond Ventures on Goldilocks AI

    Portfolio

    84

    Fund Size

    —

    Top Stage

    Series A

    Last 12 Mo

    8

    Team

    SK

    Sharon Kedar, CFA

    Co-Founder, Partner

    PM

    Paxton Major

    Managing Director

    AJ

    Andrea Jackson

    Partner

    PS

    Pat Smerkers, CPA

    Chief Financial Officer, Partner

    LC

    Lucy Coassin

    Director

    AJ

    Anjali Jagannath

    Vice President, Finance

    IL

    Ivan Learmont

    Vice President, Information Technology & Facilities

    LW

    Liz Wuestling

    Vice President, Business Analytics & Strategy

    TS

    Tim Schmidt, CPA, CFA

    Vice President, Fund Finance

    BH

    Ben Hartheimer

    Senior Associate, Portfolio Operations

    NF

    Nick Futrell

    Senior Associate

    SY

    Stephanie Yan

    Senior Associate

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    130 investments
    CompanyRoundAmountDate
    Mestag Therapeutics Limited logoMestag Therapeutics LimitedSeries B$40MMar 2026
    VieCure logoVieCureSeries A$43MJan 2026
    Vizgen logoVizgenSeries C$48MJan 2026
    Mestag Therapeutics logoMestag TherapeuticsSeed$95MJan 2026
    Mestag Therapeutics logoMestag TherapeuticsSeed$95MJan 2026
    Culture Biosciences logoCulture BiosciencesSeries C—Dec 2025
    Elephas logoElephasSeries B$40MNov 2025
    Elephas logoElephasSeries B$40MNov 2025
    EEpigenic TherapeuticsSeries B$60MSep 2025
    Epigenic logoEpigenicSeries B$60MSep 2025
    GGaruda TherapeuticsSeries A$50MMar 2025
    ENPLUSONE BIO logoENPLUSONE BIOSeed$10MFeb 2025
    Eleanor Health logoEleanor HealthSeries C$30MOct 2024
    Elephas logoElephasSeries C$55MJan 2024
    Elephas logoElephasSeries C$55MJan 2024
    Vigil Neuroscience logoVigil NeuroscienceSeries A$50MJan 2024
    VieCure logoVieCureSeries C$45MJan 2024
    Eleanor Health logoEleanor HealthSeries D—Jan 2024
    Totus Medicines logoTotus MedicinesSeries B$66MDec 2023
    Aro Biotherapeutics logoAro BiotherapeuticsSeries B$41.5MNov 2023
    KKyverna TherapeuticsSeries B$60MAug 2023
    Vital Bio logoVital BioSeries A—Jul 2023
    Refeyn logoRefeynSeries B—Apr 2023
    Vigil Neuroscience logoVigil NeuroscienceSeries B$90MJan 2023
    Sound Agriculture logoSound AgricultureSeries D$75MDec 2022
    Page 1 of 6

    Top Co-Investors

    Sands Capital16 shared
    ARCH Venture Partners16 shared
    OrbiMed13 shared
    Rock Springs Capital12 shared
    GV11 shared
    Alexandria Venture Investments10 shared
    Tao Capital Partners10 shared
    Cowen Healthcare Investments10 shared
    Windham Capital Partners10 shared
    Foresite Capital9 shared
    S328 shared
    Illumina Ventures8 shared
    SV Health Investors7 shared
    Perceptive Advisors7 shared
    Menlo Ventures7 shared
    AV8 Ventures7 shared
    Moore Strategic Ventures6 shared
    Novalis LifeSciences6 shared
    Cormorant Asset Management6 shared
    T. Rowe Price6 shared

    Last updated: 7 October 2026